Form 4: Cartesian Therapeutics Director Nishan M DeSilva Reports Stock and Option Transactions

Director Nishan M DeSilva reports acquisition of common stock and stock options in Cartesian Therapeutics.

Summary

• On January 2, 2025, Nishan M DeSilva, a director of Cartesian Therapeutics, Inc., acquired 2,600 shares of common stock at $0 and 7,800 stock options with an exercise price of $16.93.
• Following these transactions, DeSilva directly owns 8,766 shares of common stock and 7,800 stock options with an exercise price of $16.93, and 7,600 stock options with an exercise price of $19.656.
• The stock options with an exercise price of $16.93 are exercisable from January 2, 2026, to January 1, 2035.
• The stock options with an exercise price of $19.656 vest in 36 equal monthly installments following the date of grant, so that it shall be fully vested on January 2, 2027.
• The reported amounts have been adjusted to reflect a 1-for-30 reverse stock split that occurred on April 4, 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The director's acquisition of shares and options suggests confidence, but it's a routine transaction.

Positives

• The acquisition of stock and options by a director could be interpreted as a positive signal, indicating confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in the biopharmaceutical industry. Monitoring such transactions can provide insights into management's sentiment regarding the company's prospects.

Stakeholder Impact

• The transactions may have a minor positive impact on shareholder sentiment.

Key Dates